Science of uncertainty: Making cases for drug incorporation in Brazil

Anthropological Quarterly

Volumn 83, Issue 1, 2010, Pages 97-122

  Gertner, Alex ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

Brazil; Evidence making; Health economics; Pharmaceuticals; Uncertainty

Indexed keywords

EID: 77950140723     PISSN: 00035491     EISSN: None     Source Type: Journal    
DOI: 10.1353/anq.0.0116     Document Type: Article

References (44)

1. Biehl, João. 2006. "Pharmaceutical Governance." In Adriana Petryna, Andrew Lakoff and Arthur Kleinman, eds. Global Pharmaceuticals: Ethics, Markets, Practices, 206-239. Durham: Duke University Press.
2. -. 2007a. "Pharmaceuticalization: AIDS Treatment and Global Health Politics." Anthropological Quarterly 80(4):1083-1126.
3. -. 2007b. Will to Live: AIDS Therapies and the Politics of Survival. Princeton: Princeton University Press.
4. Damdron, Richard A. 1986. "Source of Funding and Outcome of Clinical Trials." Journal of General Internal Medicine I:155-158.
5. Decit (Departamento de Ciência e Tecnologia do Ministério da Saúde). 2006. "Health Technology Assessment: Institutionalization of Actions in the Brazilian Ministry of Health." Rev Saúde Pública 40(4):743-7.
6. Dobrow, Mark J, Vivek Goel and R.E.G. Upshur. 2004. "Evidence-based Health Policy: Context and Utilization." Social Science & Medicine 58:207-217.
7. Drummond, Michael. 2001. "The Use of Economic Evidence by Healthcare Decision Makers." The European Journal of Health Economics 2(1):2-3.
8. Ecks, Stefan. 2008. "Global Pharmaceutical Markets and Corporate Citizenship: The Case of Novartis' Anti-Cancer Drug Glivec." Biosocieties 3:165-181.
9. Easterbrook, Phillipa J. 1991. "Publication Bias in Clinical Research." Lancet 337:867-72.
10. Farmer, Paul. 2001. Infections and Inequalities: The Modern Plagues. Berkeley: University of California Press.
11. Geest, Sjaak van der, Susan Reynolds Whyte and Anita Hardon. 1996. "The Anthropology of Pharmaceuticals: A Biographical Approach." Annual Review of Anthropology 25:153-178.
12. Goodman, Clifford S. 2008. "HTA 101: Introduction to Health Technology Assessment." National Institutes of Health. Electronic document, http://www.nlm.nih.gov/nichsr/hta101/ta101-c1.html, accessed April 1, 2009.
13. Grangeiro, Alexandre, Luciana Teixeira, Francisco I. Bastos, and Paulo Teixeira. 2006. "Sustainability of Brazilian Policy for Access to Antiretroviral Drugs." Revista de Saúde Pública 40:60-69.
14. Guimarães, Reinaldo. 2004. "The Basis for a Brazilian National Policy in Science, Technology, and Innovation in Health." Ciência & Saúde Coletiva 9(2):375-387.
15. Healy, David. 2006. "The New Medical Oikumene." In Adriana Petryna, Andrew Lakoff and Arthur Kleinman, eds. Global Pharmaceuticals: Ethics, Markets, Practices, 61-84. Durham: Duke University Press.
16. Heres, Stephan, John Davis, Katja Maino, Elisabeth Jetzinger, Werner Kissling, and Stefan Leucht. 2006. "Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics." American Journal of Psychiatry 163(2):185-194.
17. Hutton, John, Paul Trueman and Karen Facey. 2008. "Harmonization of Evidence Requirements for Health Technology Assessment in Reimbursement Decision Making." International Journal of Technology Assessment in Health Care 24(4):511-517.
18. Kremer, Michael. 2002. "Pharmaceuticals and the Developing World." Journal of Economic Perspectives 16(4):67-90.
19. Lakoff, Andrew. 2002. "The Mousetrap: Managing the Placebo Effect in Antidepressant Trials." Molecular Interventions 2:72-76.
20. -. 2006. "High Contact: Gifts and Surveillance in Argentina." In Adriana Petryna, Andrew Lakoff and Arthur Kleinman, eds. Global Pharmaceuticals: Ethics, Markets, Practices, 111-135. Durham: Duke University Press.
21. Latour, Bruno. 1983. "Give Me a Laboratory and I Will Raise the World." In Karin D. Knorr-Cetina and Michael Mulkay, eds. Science Observed: Perspectives on the Social Study of Science. Beverly Hills: Sage Publications.
22. Marks, Harry. 1997. The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990. New York: Cambridge University Press.
23. Martin, Emily. 2007. Bipolar Expeditions: Mania and Depression in American Culture. Princeton: Princeton University Press.
24. McDonald, Maryon. 2000. Accountability, Anthropology, and the European Commission. In Marilyn Strathern, ed. Audit Culturs: Anthropological Studies in Accountability, Ethics, and the Academy, 106-132. New York: Routledge.
25. MedAdNews. 2007. Top 50 Pharmaceutical Companies Charts and Lists. Electronic document, http://www.pharmalive.com/magazines/medad/?date=09%2F2007, accessed April 1, 2009.
26. Ministério da Saúde. 2006. Portaria No 3.323 de 27 de Dezembro de 2006. http://dtr2001.saude.gov.br/sas/PORTARIAS/Port2006/GM/GM-3323. htm, accessed April 23, 2009.
27. -. 2009 Decreto no 6.860 de 27 de Maio de 2009. http://w3.datasus.gov.br/ datasus/index.php?area=01, accessed September 14, 2009.
28. Mota, Daniel Marques, Marcelo Carlos da Silva, Elisa Cazue Suido and Vicente Ortun. 2008. "Rational Drug Use: An Economic Approach to Decision Making." Ciência & Saúde Coletiva 13(Sup):589-601.
29. NICE (National Institute for Health and Clinical Excellence). 2007. Technology Appraisal Process Guides. http://www.nice.org.uk/aboutnice/howwework/ devnicetech/technologyappraisalprocessguides/technology-appraisal-process- guides.jsp, accessed April 23, 2009.
30. Niessen, Louis W., Els W.M. Grijseels and Frans F.H. Rutten. 2000. "The Evidence-Based Approach in Health Policy and Health Care Delivery." Social Science & Medicine 51:859-869.
31. PBS (Pharmaceutical Benefits Scheme). 2008. Guidelines for Preparing Submissions to PBAC. http://www.health.gov.au/internet/main/publishing.nsf/ Content/pbacguidelines-index, accessed April 23, 2009.
32. Petryna, Adriana. 2006. "Globalizing Human Subjects Research." In Adriana Petryna, Andrew Lakoff and Arthur Kleinman, eds. Global Pharmaceuticals: Ethics, Markets, Practices, 33-60. Durham: Duke University Press.
33. -. 22009. When Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Princeton: Princeton University Press.
34. Petryna, Adriana and Arthur Kleinman. 2006. "The Pharmaceutical Nexus." In Adriana Petryna, Andrew Lakoff and Arthur Kleinman, eds. Global Pharmaceuticals: Ethics, Markets, Practices, 1-32. Durham: Duke University Press.
35. Petryna, Adriana, Andrew Lakoff and Arthur Kleinman, eds. 2006. Global Pharmaceuticals: Ethics, Markets, Practices. Durham: Duke University Press.
36. Rychetnik, L., M Frommer, P Hawe, and A Shiell. 2002. "Criteria for Evaluating Evidence on Public Health Interventions" Journal of Epidemiology and Community Health 56:119-127.
37. Serra, José. 2004. "The Political Economy of the Struggle Against AIDS in Brazil." Occasional Paper (17). School of Social Science, Institute for Advanced Study.
38. Shapin, Steven and Simon Schaffer. 1985. Leviathan and the Air-pump: Hobbes, Boyle, and the Experimental Life. Princeton: Princeton University Press.
39. Smith, Richard. 2005. "Medical Journals are an Extension of the Marketing Arm of Pharmaceutical Companies." PLoS Medicine 2(5):100-102.
40. Strathern, Marilyn, ed. 2000. Audit Cultures: Anthropological Studies in Accountability, Ethics and the Academy. New York: Routledge.
41. Tunis, Sean R., Daniel B. Stryer and Carolyn M. Clancy. 2003. "Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy." JAMA 290:1624-1632.
42. Treweek, Shaun and Merrick Zwarenstein. 2009. "Making Trials Matter: Pragmatic and Explanatory Trials and the Problem of Applicability." Trials 10(37).
43. Whitmarsh, Ian. 2008. "Biomedical Ambivalence: Asthma Diagnosis, the Pharmaceutical, and Other Contradictions in Barbados." American Ethnologist 35(1):49-63.
44. World Bank. 1993. World Development Report 1993: Investing in Health. New York: Oxford University Press.